|
|
Post by mnkdacrapshoot on Mar 30, 2016 13:05:29 GMT -5
Something has to break in MNKD's favor:
a) cash setttlement and/or debt forgiveness by Sanofi --- maybe the latter, I doubt the former;
b) another BP or other regional player(s) stepping forward with upfront money for Afrezza distribution agreement;
c) RLS coming to the rescue - highly doubtful at this point;
d) Mann LOC - possibility to buy a few months;
e) More debt - possibility, but the boat is already pretty loaded at this point in this regard;
f) Another Secondary - please No at the current pps range;
g) Selling Afrezza and concentrating on TS - don't think so based on MNKD's recent moves;
What else am I missing? Comments welcome.
|
|
|
|
Post by nylefty on Mar 30, 2016 13:35:24 GMT -5
This has all been discussed here ad nauseam, but maybe as a newbie here you didn't know that. And I don't buy your premise, since the cash situation is not "desperate."
|
|
|
|
Post by spiro on Mar 30, 2016 13:47:05 GMT -5
Spiro believes that only the shorts are getting desperate, not MNKD. It's no fun paying 72.5% interest to borrow, as the share price went up from .67 to $1.68. The longer MNKD survives, the more painful and risky their gamble becomes. Even the Lyin Goldman is buying shares, so that they can loan them to the desperate shorts.
Spiro here, puffing his Afrezza and patiently waiting for the good times to return. It's only a matter of time.
|
|
|
|
Post by matt on Mar 30, 2016 15:41:18 GMT -5
The company has admitted that they need more cash to continue operating so that is a given. The list outlined in the first post is fairly comprehensive and any additions would be variations on the themes already identified. None of the sources identified are cheap money, and many are probably not even feasible, but it is the list.
The bottom line is that NOBODY on this message board has a clue what the cash position really is, and we won't know until early August. Whatever happened before the Sanofi divorce isn't relevant to the future, and the future doesn't begin until April 5th. The first glimpse of cash usage and sales results as a stand alone company won't come until the 10-Q for the second quarter which gets published in early August. Until then there are too many unknowns to say whether the company needs cash, needs cash soon, desperately needs cash, or is as good as bankrupt. A lot can happen in the next six months, both good and bad.
It serves no purpose to debate rumors; the company may have a partnership in the final stages of negotiation just like the dealer might have 16 and will have to hit it when he shows the hole card or maybe he has 21. You place your bets with imperfect facts and wait for the result.
|
|
|
|
Post by mnkdacrapshoot on Mar 30, 2016 17:37:37 GMT -5
The cash situation is critical. They have no revenue sources to speak of - Afrezza sales are practically non-existent, and they have a limited amount of cash (more and more limited as each month passes). If we don't hear of a cash infusion in some manner by June, chances of bankruptcy will, imo, be 90%. Love the drug, hate the company's financial picture.
|
|
|
|
Post by nylefty on Mar 30, 2016 17:51:27 GMT -5
The cash situation is critical. They have no revenue sources to speak of - Afrezza sales are practically non-existent, and they have a limited amount of cash (more and more limited as each month passes). If we don't hear of a cash infusion in some manner by June, chances of bankruptcy will, imo, be 90%. Love the drug, hate the company's financial picture. Where are you getting your (faulty) information? Sounds like you're parroting Jay Olson. |
|
|
|
Post by suebeeee1 on Mar 30, 2016 18:02:06 GMT -5
The cash situation is critical. They have no revenue sources to speak of - Afrezza sales are practically non-existent, and they have a limited amount of cash (more and more limited as each month passes). If we don't hear of a cash infusion in some manner by June, chances of bankruptcy will, imo, be 90%. Love the drug, hate the company's financial picture. First post on this board and you come in trying to terrorize the group. I assume you are short and despite Monday's effort to drive the share price down, it hasn't held. Too bad for you, but we have all been in that position while we watched the share price dive over the last six months. The thing that you should know about this message board is that many of us have been on here quite a while and we know the good, the bad and the ugly about this company. Most of us have conducted a great deal of due diligence and are willing to hold or shares regardless of where the short term price is. If the company ends up bankrupting because of Sanofi's efforts to hold Afrezza down, so be it. I, for one am in for the long term. You don't need to save us. Please read the topics before you decide to post points that have been discussed ad nauseam. We are more than happy to discuss points that are new or are real questions. If all you want to do is attempt to spread fear, please go away. FUD has been spread by people with far more sophisticated "observances" than you. I suggest you find a way to get out of your short positions soon. Over the next few months, I suspect (except for short term variances) that the share price will just go up. Good luck to you extracting yourself from your situation. |
|
|
|
Post by seanismorris on Mar 30, 2016 18:10:11 GMT -5
A lot of Shorts will be crawling out of the woodwork. The technicals say sell...which is what they were waiting for.
Hello fear tactics ; )
I don't think the money situation is critical yet, but it's an ongoing concern. MannKind needs to raise cash, but the terms (at the moment) aren't to their benefit.
Matt needs to report some good news then get a deal done. I'm waiting for the clinical data promised...I think Matt is waiting to do so before making a move.
New options are likely to open up soon.
|
|
|
|
Post by LosingMyBullishness on Mar 30, 2016 18:22:00 GMT -5
The funniest short I found is a daytrader who poses with some seminude girls dresses with the name of his site on their outfit. This daytrader (tatooed, day sunglasses) wrote that MNKD goes bankrupt in 4 months. Hilarious.
|
|
|
|
Post by spiro on Mar 30, 2016 18:37:33 GMT -5
Spiro loves to play craps along with his good friend and fellow Afrezza user Blindhog. Most small Biotechs are basically broke and spending money like crazy, kinda like our government does. However, few, if any of these broke Biotechs have an FDA approved product, which works great with most of their potential user's not even knowing that it exists, thanks to MNKD's deliberately incompetent ex partner Sanofi. Let's see what happens after MNKD cut's the price of Afrezza by 40-50% in a few weeks. This is something that Sanofi should have done last June. When October rolls around, money may or may not be an issue for MNKD. One thing is certain, someone will be in a lot of pain in October. Spiro is betting on the shorts being in pain. Good grief, MNKD is selling for only $1.68. Now this is a good stock to roll the dice and bet on.
Spiro here, BTW, BG is 94, 1 1/2 hours after a high carb dinner. Spiro is very thankful that he is one of the maybe 10% of diabetics, who know that Afrezza can control their diabetes. It's nice to personally know that you are betting on something that works great. One day, hopefully soon, the rest of the diabetics in the world will know this also.
John here, I had to cut Spiro off, before he started pumping. You know, that Spiro always tells the truth, but sometimes he can be too damn optimistic.
|
|
